Gestational trophoblastic diseases: new standards for therapy

被引:17
作者
Cohn, DE [1 ]
Herzog, TJ [1 ]
机构
[1] Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, St Louis, MO 63110 USA
关键词
D O I
10.1097/00001622-200009000-00017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gestational trophoblastic disease (GTD) is a spectrum of rare neoplastic conditions that are highly curable, even in the presence of widely metastatic disease. These diseases vary from partial hydatidiform mole, which rarely metastasizes and infrequently requires treatment with chemotherapy, to choriocarcinoma, for which multi-agent chemotherapy is the standard treatment. Much has been learned regarding the epidemiology of this disease, and our understanding of the genetics underlying GTD is rapidly expanding. As technology such as ultrasonography and sensitive tests for P-human chorionic gonadotropin have evolved, the presentation of molar pregnancy has significantly changed, although the incidence of persistent GTD has not decreased. This review highlights these recent advancements in the epidemiology, genetics, diagnosis, and treatment of gestational trophoblastic disease. Curr Opin Oncol 2000, 12:492-496 (C) 2000 Lippincott Williams & Wilkins, Inc.
引用
收藏
页码:492 / 496
页数:5
相关论文
共 20 条
[1]   Comparative genomic hybridization studies in hydatidiform moles and choriocarcinoma: Amplification of 7q21-q31 and loss of 8p12-p21 in choriocarcinoma [J].
Ahmed, MN ;
Kim, K ;
Haddad, B ;
Berchuck, A ;
Qumsiyeh, MB .
CANCER GENETICS AND CYTOGENETICS, 2000, 116 (01) :10-15
[2]   Telomerase activity in complete hydatidiform mole [J].
Bae, SN ;
Kim, SJ .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 180 (02) :328-333
[3]   RISK-FACTORS FOR COMPLETE MOLAR PREGNANCY FROM A CASE-CONTROL STUDY [J].
BERKOWITZ, RS ;
CRAMER, DW ;
BERNSTEIN, MR ;
CASSELLS, S ;
DRISCOLL, SG ;
GOLDSTEIN, DP .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1985, 152 (08) :1016-1020
[4]   Telomerase activity in gestational trophoblastic disease [J].
Cheung, ANY ;
Zhang, DK ;
Liu, Y ;
Ngan, HYS ;
Shen, DS ;
Tsao, SW .
JOURNAL OF CLINICAL PATHOLOGY, 1999, 52 (08) :588-592
[5]  
Coukos G, 1999, J REPROD MED, V44, P698
[6]   Hydatidiform moles and the long-term risk of breast cancer (Sweden) [J].
Erlandsson, G ;
Weiderpass, E ;
Lambe, M ;
Ekbom, A .
CANCER CAUSES & CONTROL, 2000, 11 (02) :117-120
[7]   CLINICAL RADIOIMMUNODETECTION OF CANCER WITH RADIOACTIVE ANTIBODIES TO HUMAN CHORIONIC-GONADOTROPIN [J].
GOLDENBERG, DM ;
KIM, EE ;
DELAND, FH ;
VANNAGELL, JR ;
JAVADPOUR, N .
SCIENCE, 1980, 208 (4449) :1284-1286
[8]   A NEW INTERPRETATION OF PROPORTIONALITY BETWEEN VACANCY FORMATION ENERGY AND MELTING-POINT [J].
HAYASHIUCHI, Y ;
HAGIHARA, T ;
OKADA, T .
PHYSICA B & C, 1982, 115 (01) :67-71
[9]   Genetic mapping of a maternal locus responsible for familial hydatidiform moles [J].
Moglabey, YB ;
Kircheisen, R ;
Seoud, M ;
El Mogharbel, N ;
Van den Veyver, I ;
Slim, R .
HUMAN MOLECULAR GENETICS, 1999, 8 (04) :667-671
[10]   Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors [J].
Newlands, ES ;
Mulholland, PJ ;
Holden, L ;
Seckl, MJ ;
Rustin, GJS .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :854-859